NNVC - heads up

Wednesday and Thursday hold the potential to be news days for NNVC, as both Dr. Diwan (President) and Dr. Seymour (CEO) will be featured speakers at separate conferences.  There is always a chance that something one or both of them have to say about ongoing research will ring the bell in a market moving way.


Wednesday:

3.30 p.m. – 5.00 p.m.
Session IV – The Intersection of Nanotechnology and Biology
Session Chair and Moderator – Jim Hurd, Director, NanoScience Exchange, San Francisco, CA
Prof. Brij Moudgil, Distinguished Professor and Alumni Professor of Materials Science and Engineering,
and Director of Particle Engineering Research Center, University of Florida, Gainesville, FL
Dr. Anil Diwan, President and Chairman, NanoViricides, Inc., West haven, CT,
"Nanoviricides - Novel Antiviral Agents Against HIV, Influenza, and Many Other
Diseases"

• What is a nanoviricide : "Find-Encapsulate-Destroy" antiviral strategy
• FluCide(tm) - Pan-Influenza nanoviricide against pandemic, epidemic influenzas, bird flu,
high path viruses
• HivCide(tm) - Anti-HIV nanoviricide was superior to oral HAART cocktail therapy in
animal models
• Broad-spectrum nanoviricides - A low cost approach against Neglected Tropical Diseases

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=43688654


Thursday:

NanoViricides, Inc. to Present Anti-Influenza Drug Candidate FluCide Studies at the Influenza Congress 2009

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.


Dr. Seymour will review the Company’s recent in vivo studies against influenza. The success of these studies has led the Company to consolidate its anti-influenza drug programs into a single, pan-influenza drug, “FluCide™”. This single drug is expected to be highly effective against all forms of influenza A, including the recent “swine flu” 2009/CA/H1N1 strain, seasonal flu strains, as well as H5N1 bird flu strains feared to be capable of creating a devastating pandemic, and other highly pathogenic strains on the horizon.


A “pan-influenza” drug is widely sought in order to enable treating infections from novel influenza viruses. It is well known that pandemics can be caused by novel strains of influenza. Fortunately the current “swine flu” H1N1/2009 pandemic is now believed to cause fatality rates comparable to seasonal influenzas. However, influenza viruses are known to change rapidly. New influenza viruses are often generated by mixing of genetic material from existing influenza viruses, known as “reassortments”. Such changes can lead to a novel virus that is capable of causing a wide-spread pandemic accompanied by a high fatality rate. In addition, mutations are known to have led to influenza strains resistant to existing anti-influenza drugs. The Company believes that FluCide is designed to minimize the possibility of resistant mutations.


http://finance.yahoo.com/news/NanoViricides-Inc-to-Present-bw-755360621.html?x=0&.v=1

A